Latest Peplin news

news

09-Jan-09

Positive results for Peplin's Phase IIb AK Trial read more

16-Dec-08

Peplin completes enrolment for its first phase III AK clinical trial read more

02-Dec-08

Form 10-Q - Quarterly Report read more

Registration statement including financial report read more

Frequently asked questions

Q. Why was Peplin Limited restructured under the U.S.-based parent, Peplin, Inc. in October 2007?

A. The shareholder-approved restructure of Peplin will enable the Peplin group to achieve its strategic goals as it is expected to:

  • enhance its ability to access the U.S. capital and international markets;
  • enhance its ability to attract and retain key staff with industry knowledge and experience who can advance the development and commercialization of its products in development;
  • enhance its ability to effectively manage and grow its business through alignment of its executive locations with its key markets;
  • enhance its ability to pursue acquisitions, in-licensing and other growth and diversifying opportunities in accordance with its strategic plans;
  • brings its external reporting more into line with that of many of its peers, which the board of directors believes could result in increased comparability and enhanced market understanding of its business and prospects; and
  • enable it to be a dual-listed, publicly owned company as it continues to grow internationally.

Q. How can I convert my Peplin common stock into CHESS Depositary Interests (CDIs)? Conversely, how do I convert a CDI holding to a direct holding of Peplin?

A. You will need to complete and return a form. See the Shareholder services page for instructions and forms.

Q. Where are Peplin's shares traded?

A. Peplin's shares have been listed on the Australian Securities Exchange (ASX) since September 2000. Peplin shares trade as CDIs (or CHESS Depositary Interests) under the symbol PLI.AX after a shareholder-approved reincorporation in October 2007. They previously traded under the symbol PEP.AX. Please see the following for additional ASX information.

Q. When was Peplin established?

A. Peplin was founded in 1998 and reincorporated as Peplin, Inc. in 2007. Please see the Peplin history section for further details.

Q. Where is Peplin located?

A. Peplin is headquartered in Emeryville, California, USA with offices in Brisbane, Queensland, Australia and manufacturing facilities in Southport, Queensland, Australia. Please contact us for further information.

Q. How can I receive product/trial information about Peplin?

A. Study results are published in ASX/media releases when data is available. Please sign up on Peplin's email list to automatically receive currently information about Peplin electronically. Alternatively, please see the Press releases section for all updates.

Q. How can I receive Peplin financial information?

A. Please sign up on Peplin's email list to automatically receive Peplin financial information electronically. In addition, annual reports (for the year ended June 30), half yearly reports and select quarterly financial data are available online on the Reports to shareholders section of this website.

Q. Where can I find information about Peplin's share price?

A. Peplin CDIs trade under the symbol PLI.AX after a shareholder-approved reincorporation in October 2007. They previously traded under the symbol PEP.AX. Historical prices can be found under the Share price information page.

Q. Does Peplin pay a dividend?

A. Peplin does not pay dividends at this time.

Q. What is Peplin's capital raising status?

A. Please refer to our Press releases section for Peplin's latest news and filings.

Q. Who can I contact for further information?

A. Please email or call your in-country office as per the Contact Us page.

Contact us

Medical information

Telephone: +1-800-881-5754
Email: peplin@medcomsol.com

Clinical trial information

Please refer to www.clinicaltrials.gov for trial information

Corporate information

Email: info@peplin.com

USA

6475 Christie Avenue
Suite 300
Emeryville, California 94608

Telephone: +1-510 653 9700
Facsimile: +1-510 653 9704

AUSTRALIA

Level 2, Brisbane Portal
1 Breakfast Creek Road
Newstead
Brisbane, Queensland 4006

Telephone: +61-7-3250 1200
Facsimile: +61-7-3250 1299